Successful use of venetoclax for treatment of eosinophilic dermatosis of myeloproliferative disease in a patient with chronic lymphocytic leukemia

Ann Hematol. 2020 May;99(5):1129-1131. doi: 10.1007/s00277-020-03991-x. Epub 2020 Mar 19.

Authors

Gopisree Peringeth¹, Suchitra Sundaram¹, Paul Bogner², Elizabeth Conroy³, Pallawi Torka⁴

Affiliations

¹ Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
² Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
³ Dermatology, Buffalo Medical Group, Williamsville, NY, 14221, USA.
⁴ Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, 14263, USA. Pallawi.torka@roswellpark.org.

PMID: 32193627
DOI: 10.1007/s00277-020-03991-x

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Biopsy
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Eosinophils / pathology*
Female
Humans
In Situ Hybridization
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
Middle Aged
Skin / metabolism
Skin / pathology
Skin Diseases / diagnosis
Skin Diseases / drug therapy*
Skin Diseases / etiology*
Sulfonamides / administration & dosage
Sulfonamides / adverse effects
Sulfonamides / therapeutic use*
Treatment Outcome

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax